Mike Gutch
Director of Finance/CFO at Noema Pharma AG
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Heather Elizabeth Preston | M | 58 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 16 years |
| Nicholas G. Galakatos | M | 66 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 years |
| Manoussos Perros | M | 56 |
Entasis Therapeutics Ltd.
 Entasis Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., Entasis Therapeutics Ltd. is a British pharmaceutical company founded in 2015. The private company is based in Altrincham, UK and manufactures and distributes pharmaceutical products.
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 years |
| David Hastings | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 6 years |
| Andrew J. Staples | M | 54 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 9 years |
| Heather Behanna | M | 49 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 7 years |
| James Topper | M | 62 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 8 years |
| Jan Peter Mattsson | M | 60 |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 16 years |
| David Chiswell | M | 70 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 17 years |
| Ilise Lombardo | M | - |
Noema Pharma AG
 Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | 3 years |
| Anne Klibanski | M | 73 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 5 years |
| Davey Scoon | M | 78 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 11 years |
| Roger Jeffs | M | 62 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 6 years |
| Ronald Cooper | M | 61 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | - |
| David Meek | M | 59 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 years |
| Darren J. Carroll | M | - |
Noema Pharma AG
Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | - |
| Per-Göran Gillberg | M | 68 |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | 26 years |
| David Altarac | M | 63 |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | 5 years |
| Ronald Lauder | M | 80 |
Alzheimers Drug Discovery Foundation
 Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Catherine Moukheibir | F | 64 |
Noema Pharma AG
Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | 3 years |
| Paula Boggs | F | 64 |
The Johns Hopkins University
| - |
| Howard Fillit | M | - |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | 26 years |
| Leonard Lauder | M | 91 |
Alzheimers Drug Discovery Foundation
Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr. | - |
| Beth Marek | F | - |
The Johns Hopkins University
| - |
| David Hodgson | M | 67 |
The Johns Hopkins University
| - |
| Jeff Jonas | M | 71 |
Noema Pharma AG
Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | 3 years |
| Pam Cheng | F | 53 | 9 years | |
| Rick Inglis | M | - |
The Johns Hopkins University
| - |
| Daniela Schwarzer | M | 50 |
The Johns Hopkins University
| - |
| Sol Kumin | M | 48 |
The Johns Hopkins University
| - |
| Myeong-Geun Lee | M | 66 |
The Johns Hopkins University
| - |
| Julia Buick | F | - |
The Johns Hopkins University
| - |
| Kent Calder | M | - |
The Johns Hopkins University
| - |
| Melissa Arnie | F | - |
The Johns Hopkins University
| - |
| Yaacov Rubin | M | - |
The Johns Hopkins University
| - |
| Kenneth J. Pienta | M | 64 |
The Johns Hopkins University
| 30 years |
| Israel Gannot | M | - |
The Johns Hopkins University
| - |
| Faisal Abualhassan | M | - |
The Johns Hopkins University
| - |
| N. Cinnamon Dornsife | F | - |
The Johns Hopkins University
| - |
| Michael P. Boyle | M | - |
The Johns Hopkins University
| - |
| Susan Wismar | F | - |
The Johns Hopkins University
| - |
| Meghan Stark | F | - |
The Johns Hopkins University
| - |
| Naneen Neubohn | F | - |
The Johns Hopkins University
| - |
| Mario Eisenberger | M | 74 |
The Johns Hopkins University
| 31 years |
| Tyrell J. Rivers | M | 51 | 10 years | |
| Kevin Schollenberger | M | - |
The Johns Hopkins University
| - |
| Tony Ho | M | 58 |
The Johns Hopkins University
| - |
| Jennifer Calhoun | F | - |
The Johns Hopkins University
| - |
| Ann Koch | F | - |
The Johns Hopkins University
| - |
| Charles Lowenstein | M | - |
The Johns Hopkins University
| - |
| Natalie Lorenz-Anderson | F | 61 |
The Johns Hopkins University
| - |
| Dorothy Sheppard | F | - |
The Johns Hopkins University
| - |
| Bonnie Windsor | F | - |
The Johns Hopkins University
| - |
| Mark Lowenthal | M | - |
The Johns Hopkins University
| - |
| Adam Levin | M | 45 |
The Johns Hopkins University
| - |
| Ming Zhao Xing | M | 62 |
The Johns Hopkins University
| 13 years |
| Michele Moore | F | - |
The Johns Hopkins University
| - |
| Walter Pinkard | M | - |
The Johns Hopkins University
| - |
| Kathleen L. Kiernan | M | - |
The Johns Hopkins University
| - |
| Timothy S. Fallon | M | 61 |
The Johns Hopkins University
| - |
| Benjamin Griswold | M | 83 |
The Johns Hopkins University
| - |
| Ronald M. Nordmann | M | 82 |
The Johns Hopkins University
| - |
| Frank Savage | M | 85 |
The Johns Hopkins University
| - |
| Guenther E. Greiner | M | 85 |
The Johns Hopkins University
| - |
| William C. Richardson | M | 82 |
The Johns Hopkins University
| 34 years |
| Brian Rogers | M | 68 |
The Johns Hopkins University
| - |
| Norm Augustine | M | 88 |
The Johns Hopkins University
| - |
| Karen Peetz | F | 68 |
The Johns Hopkins University
| - |
| Roger Conant Faxon | M | 75 |
The Johns Hopkins University
| - |
| David Sidransky | M | 64 |
The Johns Hopkins University
| 26 years |
| Paul M. Ness | M | 78 |
The Johns Hopkins University
| 45 years |
| Ronald Daniels | M | 64 |
The Johns Hopkins University
| 15 years |
| Rudolf Christopher Hoehn-Saric | M | 61 |
The Johns Hopkins University
| - |
| Mayo Shattuck | M | 69 |
The Johns Hopkins University
| - |
| Antonia Hernández | F | 75 |
The Johns Hopkins University
| - |
| Stewart Bainum | M | 77 |
The Johns Hopkins University
| - |
| Jeffrey S. Barber | M | 51 |
The Johns Hopkins University
| - |
| Charles I. Clarvit | M | 68 |
The Johns Hopkins University
| - |
| Clayton A. Ajello | M | - |
The Johns Hopkins University
| - |
| Scott Semple | M | - |
The Johns Hopkins University
| - |
| James R. Calvin | M | - |
The Johns Hopkins University
| - |
| Kay Kapoor | F | 61 |
The Johns Hopkins University
| - |
| Michela Gallagher | M | - |
The Johns Hopkins University
| - |
| Mario Garraffo | M | 86 |
The Johns Hopkins University
| - |
| Gerald M. Masson | M | - |
The Johns Hopkins University
| - |
| Ankit Mahadevia | M | 43 |
The Johns Hopkins University
| - |
| Samuel R. Denmeade | M | - |
The Johns Hopkins University
| - |
| Ashok Kumar Agarwal | M | 67 |
The Johns Hopkins University
| - |
| Joseph E. Foss | M | - |
The Johns Hopkins University
| - |
| Michael I. Miller | M | - |
The Johns Hopkins University
| - |
| Rajeev Kumar Goel | M | 46 |
The Johns Hopkins University
| - |
| Raj Ananthanpillai | M | - |
The Johns Hopkins University
| - |
| Barbara White | M | 73 |
The Johns Hopkins University
| - |
| Levi Watkins | M | - |
The Johns Hopkins University
| - |
| Bahija Jallal | M | 62 |
The Johns Hopkins University
| 10 years |
| Laurence M. Merlis | M | - |
The Johns Hopkins University
| - |
| Kristina Snyder | F | - |
The Johns Hopkins University
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas A. Shea | M | 64 |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | - |
| Vanessah Ng | F | - |
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | 2 years |
| Ann Cairns | F | 67 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 90 | 90.00% |
| Sweden | 7 | 7.00% |
| United Kingdom | 5 | 5.00% |
| Switzerland | 4 | 4.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mike Gutch
- Personal Network
